Price floor for Bayer shares may not exist as Monsanto glyphosate-cancer litigation costs mount

| | July 1, 2019
Bayer Monsanto Merger
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

On June 7th, 2018, Bayer …. consummated its $63 billion acquisition of Monsanto, the largest GMO and agricultural chemical distributor in the world.

Immediately following the merger, a landmark case was awarded against Monsanto in regards to the sale of the world’s mostly widely used herbicide, glyphosate, causing non-Hodgkin’s lymphoma after long-term exposure …. In this case, the plaintiff, Dwayne Johnson, was awarded over $289 million (reduced to $78 million in an appeal) in compensatory and punitive damages for negligence on behalf of Monsanto in failure to disclose the relevant health hazards. Since then, over 13,400 lawsuits are now pending against Bayer-Monsanto in regards to the carcinogenic nature of the its agricultural chemical.

Related article:  IARC assessment of glyphosate only served to confuse policy makers, public

After an examination of relevant observations; epidemiological statistics, clinical data, legal precedents, international perspectives, and a 630 page report from the State of California regarding the chemical’s ban, the author finds due to the severity of these allegations; Bayer may not be able to prove its innocence due to the impossibility of running clinical trials regarding the safety of this herbicide on humans. This puts the company completely at the mercy of barristers ….

Read full, original article: Glyphosate’s Non-Carcinogen Status Unverifiable. Price Floor May Not Exist For Bayer Shares

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend